NCT01636843终止2 期
A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 298
- 试验地点
- 1
- 主要终点
- ACR20 (defined as 20% improvement in American College of Rheumatology criteria measures)
研究概览
简要总结
This trial is conducted in Europe, North America and South America. The aim of this trial is to investigate the clinical efficacy of NNC0109-0012, a human monoclonal antibody, compared to placebo when administered as weekly repeat subcutaneous (under the skin) injections in to patients with active rheumatoid arthritis (RA) with inadequate responses to methotrexate (MTX) while on a stable background of MTX therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent must be obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial - A documented diagnosis of RA at least 6 months prior to screening visit, according to the American College of Rheumatology (EULAR/ACR 2010 criteria) or by standard criteria (ACR 1987) if diagnosis was made earlier than 2010 - Active RA, characterised by: a. more than 5 tender and more than 5 swollen joints based on a 28 joint count b. C-reactive protein (CRP) above or equal to 1.0 mg/dL (10 mg/L) - Patients can be on methotrexate with or without hydroxychloroquine/chloroquine: a. Methotrexate treatment (above or equal to 15.0 mg/week) for at least 16 weeks, (above or equal to 15.0 mg/week to below or equal to 25 mg/week) for at least 8 weeks prior to screening. Patient can be on MTX as low as 10 mg/week only if due to MTX intolerance b. Hydroxychloroquine (200-400 mg/day per os, oral dosing (p.o.)) or chloroquine (250-500 mg/day p.o.) treatment for at least 8 weeks prior to screening visit
排除标准
- •Patients with arthritis due to other autoimmune diseases than RA - Any active or ongoing bacterial infections within 4 weeks prior to screening visit, unless treated and resolved with appropriate therapy or any history of recurrent infections or conditions predisposing to chronic infections (e.g., bronchiectasis, chronic osteomyelitis) - History of severe, systemic viral or fungal infections within the past 6 months prior to screening visit, unless treated and/or resolved with appropriate therapy - Patients with active malignancy within the previous 5 years with the exception of adequately treated and cured basal or squamous cell carcinoma of the skin or cervical carcinoma in situ occurring more than 12 months prior to screening visit - Females of childbearing potential who are pregnant or breast feeding or intend to become pregnant - Any other disease or clinically significant abnormality in laboratory parameters which, according to the Investigator, might compromise the safety of the patient, interfere with participation in the trial or compromise the trial objective
研究组 & 干预措施
60 mg
Experimental
干预措施: NNC0109-0012 (Drug)
120 mg
Experimental
干预措施: NNC0109-0012 (Drug)
240 mg
Experimental
干预措施: NNC0109-0012 (Drug)
Placebo
Experimental
干预措施: placebo (Drug)
结局指标
主要结局
ACR20 (defined as 20% improvement in American College of Rheumatology criteria measures)
时间窗: At week 12 (responder or non-responder)
次要结局
- Simplified Disease Activity Index (SDAI) remission (SDAI of 3.3 or below)(At weeks 12 and 24)
- European League Against Rheumatism (EULAR) criteria response(At weeks 12 and 24)
- Change from baseline in the overall scores of Health Assessment Questionnaire - Disability Index (HAQ-DI)(At weeks 12 and 24)
- ACR20/50/70 (20%, 50% or 70% improvement of ACR (American College of Rheumatology) score from baseline)(Week 52)
- Change from baseline in the overall scores of Short Form Health Survey (SF-36v2)(At weeks 12 and 24)
- Incidence and type of adverse events (AEs)(Week 52)
- Change from baseline in van der Heijde modified Sharp score(At weeks 12 and 24)
- Change in DAS28-CRP (defined as Disease Activity Score for 28 joints with C-reactive protein measure) from baseline(At weeks 12 and 24)
- ACR20, ACR50 and ACR70 improvement of ACR score from baseline(At weeks 12 and 24)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa BiologicsInflammationRheumatoid ArthritisNCT01636817Novo Nordisk A/S239
已完成
2 期
Recombinant Factor VIIa in Acute Intracerebral HaemorrhageAcquired Bleeding DisorderIntracerebral HaemorrhageNCT00426803Novo Nordisk A/S400
终止
1 期
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)InflammationSystemic Lupus ErythematosusNCT01689025Novo Nordisk A/S10
已完成
2 期
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's DiseaseInflammationCrohn's DiseaseNCT01751152Novo Nordisk A/S53
已完成
2 期
Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain InjuryAcquired Bleeding DisorderTraumaNCT00123591Novo Nordisk A/S96